

해외 바이오의약품 임상 현황 ('23년 1월 1주)

한국바이오의약품협회, 2023.01.10.

※ ClinicalTrials.gov에 등록된 국가별 바이오의약품 임상시험 목록(병용요법 포함)을 한국바이오의약품협회에서 주간 업데이트하여 제공합니다.
URL을 클릭하시면 세부 정보 페이지로 연결됩니다.
- 출처: ClinicalTrials.gov
- 모니터링 기간: 2023.01.02. ~ 2023.01.08.
- 주간 업데이트 제공국가 : 미국, 유럽(영국, 프랑스, 독일), 중국, 일본

○ 미국 10건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05455697	Tafasitamab, Retifanlimab, and Rituximab in Combination With Chemotherapy (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) for the Treatment of Diffuse Large B-cell Lymphoma	Procedure: Biopsy Drug: Cyclophosphamide Drug: Doxorubicin Drug: Prednisone Biological: Retifanlimab Biological: Rituximab and Hyaluronidase Human Biological: Tafasitamab Drug: Vincristine	University of Washington	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05455697
NCT05284604	Mesenchymal Stem Cells for Age-Related Frailty	Drug: Mesenchymal Stem Cells (MSCs)	VA Office of Research and Development Michael E. DeBakey VA Medical Center Baylor College of Medicine	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05284604
NCT05159453	Dose Response Study of Transdermal Human Insulin in Patients	Biological: Human Insulin Device: Finger-actuated, Metered Pump Sprayer	Transdermal Delivery Solutions Corp Langford Research Institute, Inc.	Phase 2 Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05159453
NCT05634577	A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical Carcinoma	Drug: Mitotane Drug: Pembrolizumab	M.D. Anderson Cancer Center	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05634577
NCT05568550	Pembro With Radiation With or Without Olaparib	Biological: Pembrolizumab Drug: Olaparib Drug: Androgen Deprivation Therapy Radiation: Radiation Therapy	Zin W Myint Merck Sharp & Dohme LLC University of Kentucky	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05568550
NCT05464329	Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Autologous Stem Cell Transplant-Eligible Patients With Relapsed/Refractory Aggressive B Cell Lymphoma	Drug: Mosunetuzumab Drug: DHAX Drug: ICE	Washington University School of Medicine Genentech, Inc.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05464329
NCT04466475	Radioimmunotherapy (211At-OKT10-B10) and Chemotherapy (Melphalan) Before Stem Cell Transplantation for the Treatment of Multiple Myeloma	Biological: Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10 Drug: Melphalan Procedure: Peripheral Blood Stem Cell Transplantation	Fred Hutchinson Cancer Center National Cancer Institute (NCI) National Institutes of Health (NIH)	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT04466475
NCT05590377	A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma	Drug: Modakafusp Alfa Drug: Daratumumab	Takeda	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05590377
NCT05649137	A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight	Drug: Semaglutide Drug: Placebo	Novo Nordisk A/S	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05649137
NCT05646706	A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP)	Drug: Semaglutide Drug: Placebo	Novo Nordisk A/S	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05646706

○ 영국 1건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05590377	A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma	Drug: Modakafusp Alfa Drug: Daratumumab	Takeda	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05590377

○ 프랑스 2건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05622071	Testing Immunotherapy for Patients With Liver Cancer and Moderately Altered Liver Functions	Drug: Tislelizumab	UNICANCER	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05622071
NCT05590377	A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple	Drug: Modakafusp Alfa Drug: Daratumumab	Takeda	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05590377

해외 바이오의약품 임상 현황 ('23년 1월 1주)

한국바이오의약품협회, 2023.01.10.

○ 독일 3건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT04808245	A MulticENTER Phase I Peptide VaCcine Trial for the Treatment of H3-Mutated Gliomas	Drug: Tecentriq 1200 MG in 20 ML Injection Biological: H3K27M peptide vaccine Other: Imiquimod (5%)	German Cancer Research Center Johannes Gutenberg University Mainz Charite University, Berlin, Germany Roche Pharma AG German Cancer Aid	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT04808245
NCT05646706	A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP)	Drug: Semaglutide Drug: Placebo	Novo Nordisk A/S	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05646706
NCT05590377	A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma	Drug: Modakafusp Alfa Drug: Daratumumab	Takeda	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05590377

○ 중국 4건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05590377	A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma	Drug: Modakafusp Alfa Drug: Daratumumab	Takeda	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05590377
NCT05631964	Phase I Clinical Study of BL-M07D1 in Locally Advanced or Metastatic Digestive Tract Tumors and Other Solid Tumors	Drug: BL-M07D1	Sichuan Baili Pharmaceutical Co., Ltd. SystImmune Inc.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05631964
NCT05225116	Safety and Efficacy of Lenvatinib and Anti-PD1 Antibody Combined With Radiotherapy Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT	Drug: Sintilimab Drug: Lenvatinib Radiation: radiotherapy	Beijing Tsinghua Chang Gung Hospital	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05225116
NCT05652543	A PhaseII Study to Evaluate the Safety & Immunogenicity of SARS-CoV-2 Alpha/Beta/Delta/Omicron Variants COVID-19 Vaccine	Biological: SCTV01E Biological: Placebo (normal saline)	Sinocelltech Ltd.	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05652543